BioPorto Diagnostics


DKK529.8m market cap

DKK2.65 last close

BioPorto Diagnostics is a diagnostic company focused on the development and commercialisation of biomarker-based assays. The company’s portfolio includes The NGAL Test, for prediction of acute kidney injury, and an extensive antibody library.

Investment summary

BioPorto’s lead strategic goal is development of a test for acute kidney injury (AKI) using the biomarker NGAL. The company is gathering more data for its pediatric urine NGAL 510(k) and expects to submit in H220. For adults using plasma NGAL, the pivotal clinical trial is being completed with the 510(k) to be submitted to the FDA after the submission for pediatric. The NGAL Test is commercially available for research purposes in the US and has been CE marked in Europe. BioPorto also sells a series of other antibodies, ELISA kits and related biologics.

Y/E Dec
Revenue (DKKm)
EPS (ore)
P/E (x)
P/CF (x)
2018A 26.0 (42.1) (42.5) (24.34) N/A N/A
2019A 26.6 (68.3) (71.1) (39.16) N/A N/A
2020E 27.0 (60.1) (63.4) (31.03) N/A N/A
2021E 101.2 (8.3) (9.7) (4.54) N/A N/A
Industry outlook

The current standard of care for detecting AKI is serum creatinine, which can take 24 hours or more to detect AKI and can only do so after significant kidney damage. NGAL promises to provide a quicker and more reliable test, allowing early intervention to preserve kidney function.

Last updated on 15/07/2020
Share price graph
Balance sheet
Forecast net cash (DKKm) 0
Forecast gearing ratio (%) N/A
Price performance
Actual 1.9 (10.2) (32.0)
Relative* (2.7) (22.6) (46.3)
52-week high/low DKK3.4/DKK1.7
*% relative to local index
Key management
Thomas Magnussen Chairman
Peter Mørch Eriksen CEO
Ole Larsen CFO
Jan Kuhlmann Andersen COO